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Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) has challenged public 28 
health agencies globally. In order to effectively target government responses, it is critical to 29 
identify the individuals most at risk of coronavirus disease-19 (COVID-19), developing 30 
severe clinical signs, and mortality. We undertook a systematic review of the literature, to 31 
present the current status of scientific knowledge in these areas and describe the need for 32 
unified global approaches, moving forwards, as well as lessons learnt for future pandemics. 33 
 34 
Methods 35 
Medline, Embase and Global Health were searched to the end of April 2020, as well as the 36 
Web of Science. Search terms were specific to the SARS-CoV-2 virus and COVID-19. 37 
Comparative studies of risk factors from any setting, population group and in any language 38 
were included. Titles, abstracts and full texts were screened by two reviewers and extracted 39 
in duplicate into a standardised form. Data were extracted on risk factors for COVID-19 40 
disease, severe disease, or death and were narratively and descriptively synthesised. 41 
 42 
Results 43 
1,238 papers were identified post-deduplication. 33 met our inclusion criteria, of which 26 44 
were from China. Six assessed the risk of contracting the disease, 20 the risk of having 45 
severe disease and ten the risk of dying. Age, gender and co-morbidities were commonly 46 
assessed as risk factors. The weight of evidence showed increasing age to be associated 47 
with severe disease and mortality, and general comorbidities with mortality. Only seven 48 
studies presented multivariable analyses and power was generally limited. A wide range of 49 
definitions were used for disease severity. 50 
       51 




The volume of literature generated in the short time since the appearance of SARS-CoV-2 54 
has been considerable. Many studies have sought to document the risk factors for COVID-55 
19 disease, disease severity and mortality; age was the only risk factor based on robust 56 
studies and with a consistent body of evidence. Mechanistic studies are required to 57 
understand why age is such an important risk factor. At the start of pandemics, large, 58 
standardised, studies that use multivariable analyses are urgently needed so that the 59 
populations most at risk can be rapidly protected.  60 
 61 
This review was registered on PROSPERO as CRD42020177714. 62 
 63 
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The world is currently experiencing a pandemic of coronavirus disease (COVID-19) caused 67 
by the Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2).(1) The risk of 68 
morbidity and mortality from the virus is strongly stratified, with poor clinical outcomes 69 
considered more likely in certain vulnerable groups. For example, studies from different 70 
countries have established that older age groups are at increased risk of death.(2, 3)  71 
 72 
The ability to identity the population groups most at risk from the virus has manifold public 73 
health purposes. Using such data, stratified vaccination policies for governmental delivery 74 
can be designed, similar to those for influenza.(4) It may also be possible to prioritise more 75 
active monitoring of groups more at risk of clinical deterioration, and facilitate access to 76 
healthcare facilities by early identification of the individuals most likely to progress to severe 77 
disease who would thus be in need of intensive care and ventilation. Official advice can be 78 
issued to vulnerable groups to let them know that they are more at risk from SARS-CoV-2 79 
virus, to promote behaviour modification.(5, 6) Such population groups can also be the target 80 
of more formalised ‘segment and shield’ approaches: having divided the population into 81 
groups that present with similar health care concerns and needs (segmenting) it is possible 82 
to determine which groups require extra protection by reducing interaction with other groups 83 
(shielding), whilst relaxing restrictions for the rest of the population.(7) Potential public health 84 
policies along this route have been critiqued, however, on an inclusivity basis, particularly 85 
due to the unintended harmful consequences to already marginalised groups.(8) 86 
 87 
In the UK, vulnerable people were stratified into two tiers by 30th March 2020 (Table 1); 88 
those at risk of severe illness, who were advised to be particularly stringent with social 89 
distancing measures, and those within that group at further risk – described as ‘shielded’ 90 
individuals – who were advised to self-isolate and were provided with additional advice.(9-91 
12) The former categorisation was based on the groups targeted for National Health Service 92 
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programmes on influenza vaccination and the latter on clinical consensus. These strata were 93 
deliberately broad, to maximise the number of individuals protected. As the evidence evolves 94 
– e.g. regarding whether the development of  lesions in the cardiovascular system 95 
contributes meaningfully to disease pathogenesis in patients with and without pre-existing 96 
cardiovascular conditions(13) – there is the opportunity for the categorisation of risk of 97 
COVID-19 and serious outcomes from COVID-19 to become more evidence-based. 98 
 99 
During epidemics and pandemics of emerging infectious diseases, it is critical to rapidly and 100 
accurately identify the populations most at risk. In the case of COVID-19, we undertook a 101 
systematic review and quality assessment of the rapidly-evolving global literature in this 102 
area, looking at three key outcomes: COVID-19 disease, disease severity, and mortality from 103 
the condition. Any potential risk factors, populations, and study designs were included. 104 
Arising from our findings, we highlight key knowledge gaps in the current literature and the 105 
need for unified global approaches moving forwards, particularly for the next pandemic. 106 
 107 
 108 
Materials and methods 109 
Literature search 110 
We systematically searched Medline, Embase, and Global Health (all via the Ovid platform), 111 
in addition to the Web of Science, for published literature between 1st November 2019 and 112 
26th March 2020; then subsequently updated this search for a later period to 29th April. In 113 
order to avoid missing publications on risk factors, only terms specific to the virus and the 114 
disease were used, which were combined with ‘or’: 115 
 ‘coronavirus’ 116 
 ‘covid-19’ 117 
 ‘severe acute respiratory syndrome coronavirus 2’ 118 
 ‘2019-nCoV-2’ 119 
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 ‘SARS-CoV-2’ 120 
 ‘acute respiratory syndrome’ 121 
No limits or filters were applied to the search. The same search terms were used across all 122 
databases. 123 
 124 
Reference lists of included papers and review articles were also searched, as was the grey 125 
literature of public health reports for the 26 countries with the highest numbers of reported 126 
patients with COVID-19 at the end of April 2020, for other countries it was assumed there 127 
would be insufficient numbers of cases to yield relevant data. 128 
 129 
Eligibility criteria and study selection 130 
The following inclusion and exclusion criteria were applied to the search results. 131 
 132 
Inclusion criteria: 133 
 Studies had to provide comparative data on risk factors of any kind for disease 134 
(versus no disease), severe disease (versus milder disease) or mortality (versus 135 
survival), 136 
 Studies were eligible if they presented data on patients with polymerase chain 137 
reaction (PCR)-confirmed SARS-CoV-2 infections. There was considerable variation 138 
in case definitions between studies, but PCR testing was the gold standard test for 139 
active disease at the start of the pandemic,(14) and other testing methods such as 140 
Loop-Mediated Isothermal Amplification or serological tests were not included, or , 141 
 Any study design, 142 
 Any population group, 143 
 Any language of publication. 144 
 145 
Exclusion criteria: 146 
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 No comparator group included in the study, 147 
 Publication concerned other viruses and diseases, 148 
 Work conducted in animals or in vitro, 149 
 Study population was less than 20 individuals. 150 
 151 
Two reviewers independently screened all titles, abstracts and full texts for both literature 152 
searches. Discrepancies were resolved by consensus. In all cases where studies were 153 
published in any language other than English, with no translations available, these were 154 
screened by at least one additional reviewer, with further quality control by another member 155 
of the reviewing team. 156 
 157 
Data extraction 158 
Three reviewers independently double-extracted the studies into a pre-designed 159 
spreadsheet that collected: 160 
 First author, 161 
 Paper title, 162 
 Journal, 163 
 Type of study, 164 
 Country, 165 
 Study population, 166 
 Overall number in study, 167 
 Number with PCR confirmed SARS-CoV-2, 168 
 Median age of participants/age range, 169 
 Sex ratio, 170 
 Analytical method used, 171 
 Factors adjusted for during the analysis, 172 
 Whether disease, disease severity, or death (or a combination of these) was the 173 
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outcome of interest, 174 
 The definition of disease severity used, if applicable, 175 
 The risk factors analysed and the direction of effect. 176 
Results were compared and discrepancies resolved by discussion. Data from studies 177 
published in languages other than English, at this stage only the Chinese language, were 178 
extracted by two additional reviewers, with further quality control by another member of the 179 
reviewing team. 180 
 181 
Quality assessment 182 
Two reviewers independently assessed the quality of included studies. Studies published in 183 
languages other than English were quality assessed by two additional reviewers, with further 184 
quality control by another member of the reviewing team. Assessments were undertaken 185 
from the perspective of the objectives of this review, which were not necessarily identical to 186 
the objectives of the underlying studies. The quality of included studies was assessed using 187 
a checklist adapted from Downs and Black,(15) as per the guidance issued by Deeks et 188 
al.(16) When assessing the power of studies, the minimum sample size required to detect a 189 
relative increase in risk of 10% from a statistically conservative baseline of 50% among the 190 
unexposed was calculated at different powers using the Kelsey method within Epi Info, 191 
software made available by the United States Center for Disease Control.(17) This 10% 192 
value was based on governmental discussions taking place in the UK at the time the review 193 
took place. An alpha of 5% was set as the standard. Pragmatically, we assumed only two 194 
strata and a ratio of 1:1 between exposure strata. Different thresholds were used for case-195 
control studies and for cohort or cross-sectional studies. These criteria were scored from 0 196 
(<70% power) to 5 (>99% power). We considered results sufficient adjusted for confounding 197 
if they adjusted for at least the minimal variable set of age, sex, ethnicity and any measure of 198 
comorbidities. For ethnically homogenous populations, the need for adjustment for ethnicity 199 
was discounted. If two analyses were presented within a single paper with different quality 200 
scores, the most conservative score was retained. Studies were not excluded on the basis of 201 
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the quality assessment. 202 
 203 
Analysis and synthesis 204 
Studies were grouped on the basis of the outcome examined (disease, disease severity, 205 
mortality) and then the risk factors examined. Results were classified on the basis of whether 206 
they presented evidence as to the exposure under study being a risk factor, taking into 207 
account the number of individuals exposed. Where studies focussed on a single risk factor of 208 
interest with adjustment for confounding, we extracted all data on potential risks in order to 209 
maximise the value of our dataset (whilst accepting that such mutually adjusted estimates for 210 
covariates may remain confounded even if that for the primary exposure does not).(18) As 211 
there was substantial heterogeneity in study design, reporting, and the risk factors 212 
examined, we present a detailed descriptive summary and narrative synthesis of our 213 
findings, rather than a meta-analysis. 214 
 215 
Registration and reporting 216 
This review was registered on PROSPERO as CRD42020177714 and is reported according 217 




2,868 hits were obtained by the searches across the two dates (Figure 1). After de-222 
duplication across the different databases, this was reduced to 1,238. 30 studies were 223 
included at the extraction stage; the main reasons for exclusion were small numbers of 224 
participants and studies not having a comparator population. From the grey literature an 225 




Included studies are presented in Table 2. 29 of the 33 studies were conducted in China, 228 
with one each from France, Italy, Singapore and a combined study from England, Wales and 229 
Northern Ireland. Six were studies with COVID-19 disease as the outcome, 20 of disease 230 
severity and ten of mortality. One additional study looked at a combined outcome of disease 231 
severity and mortality. (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), (29), (30), (31), (32), 232 
(33), (34), (35), (36), (37), (38), (39), (40), (41), (42), (43), (44), (45), (46), (47), (48), (49), (50), (51) 233 
Quality assessment 234 
Included studies were generally too small to detect a 10% increase in risk of disease, 235 
disease severity, or mortality (Table 3). One study among the 33 was assessed to have 95% 236 
power and two others 99%; all were large, national, investigations. As 26 studies were purely 237 
descriptive or presented univariable analysis only, there was no adjustment for confounding. 238 
Remaining studies with a regression component did not adjust for our minimal confounder 239 
set. Only nine studies provided estimates of the random variability of effect estimates. The 240 
majority of studies ascertained exposure information from clinical records, which would have 241 
collected data prospectively and thus with limited recall bias. Blinding of outcome and 242 
exposure recording by investigators was not documented. In the case of certain disease 243 
severity outcomes, such as admittance to intensive care units (ICU), variability in thresholds 244 
for reaching these outcomes is likely to exist between settings and clinicians 245 
 246 
Risk factors for disease 247 
Six studies compared the likelihood of having COVID-19 to other infectious conditions (Table 248 
4). Of note, as testing strategies were largely focussed on hospitalised individuals i.e. those 249 
displaying noticeable symptoms, studies were of the likelihood of COVID-19 disease, rather 250 
than more broadly of SARS-CoV-2 infection (and particularly of severe disease, although 251 
patients with mild and symptomatic infection were also reported to be hospitalised in some 252 
studies for the purposes of isolation or observation). Age and sex were key foci as potential 253 
risk factors, comparing patients with COVID-19 to either: a) SARS-CoV or Middle Eastern 254 
Respiratory Syndrome (MERS), or b) other forms of pneumonia. Generally, sex ratios were 255 
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skewed such that men were over-represented among those with disease. In England, 256 
Northern Ireland, and Wales, Asian and Black individuals were found to be at increased risk 257 
of COVID-19 in descriptive analyses, with 15.4% and 10.7% of patients falling into these 258 
groupings, respectively, versus 5.8% and 2.8% of  individuals with other viral 259 
pneumonia.(30) Higher body mass index (BMI) was also suggested to be a risk factor with 260 
two descriptive analyses, for example in the Intensive Care National Audit and Research 261 
Centre (ICNARC) report 31.2% of COVID-19 patients had a BMI of 30-<40, versus 23.5% of 262 
people with other viral pneumonia.(30, 37) Given the large, national, scope of the ICNARC 263 
dataset, results from it are particularly likely to be reliable. 264 
 265 
Risk factors for severe disease 266 
Among the 20 studies of risk factors for severe versus milder disease and one of a mixed 267 
outcome (severe disease and death), a wide array of definitions of severity were used, such 268 
as ICU admission, the need for mechanical ventilation, and various measures of respiration 269 
and oxygenation (Table 2). Many risk factors were examined (Table 5). As well as potential 270 
demographic risks (age, sex, ethnicity), behavioural traits (smoking) and broad clinical 271 
factors (BMI, infectious diseases) were analysed. Large numbers of papers sought to 272 
explore the implications of different comorbidities on the risk of severe COVID-19, 273 
particularly respiratory and cardiovascular conditions. 274 
 275 
The least equivocal evidence was presented for age as a risk factor, including four studies 276 
where it was an independent risk in a multivariable regression model.(19, 20, 31, 36) The 277 
clearest analysis to present age data (i.e. which used different comparison groups) was a 278 
univariable regression model where individuals 65 years and over had 3.26 times the hazard 279 
rate of ARDS than those under 65.(44) Eight studies suggested that diabetes could be a risk 280 
factor,(19, 31, 36, 39, 41, 43, 44, 50) six hypertension,(31, 36, 41, 43, 44, 50) and four the 281 
presence of unspecified comorbidities)(39, 41, 48, 50), but the balance of evidence for these 282 
co-morbidities being risk factors was generally inconclusive. Many other factors were 283 
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examined by one study, often with small numbers of individuals with the condition. None of 284 
the included studies for disease severity were assessed to have been powered to detect a 285 
10% increase in effect size. 286 
 287 
Risk factors for mortality 288 
Ten studies examined risk factors for mortality, often by nesting case-control studies within 289 
prospective or retrospective cohorts (Table 6). Among these studies, many included 290 
statistical testing, but none presented an adjusted regression model for the risk factors 291 
considered. 292 
 293 
Eight studies examined age and all provided evidence for it being a risk factor for 294 
mortality,(21, 25, 27, 35, 44-47) although none adjusted for other factors, such as 295 
comorbidities. Age groups from 50 upwards were considered particularly at risk. In the single 296 
regression analysis, the hazard rate for death in those 65 years or over was estimated to be 297 
six times that of individuals under 65.(44) The evidence was similarly consistent for general 298 
comorbidities (albeit all the studies were descriptive); among individuals who died, 299 
comorbidities were 1.5 to 2.8 times more common than among those who survived.(21, 35, 300 
46, 47, 51) Specific comorbidities were discussed in several studies, generally under 301 
overarching classifications such as ‘cardiovascular disease’ or ‘diabetes’, with more specific 302 
definitions not provided. Evidence was more equivocal, but still in favour, of hypertension,(3, 303 
21, 25, 27, 47, 51) cardiovascular disease,(21, 25, 35, 45, 47, 51) diabetes,(21, 25, 45-47, 304 
51) and chronic respiratory/lung diseases being risk factors (references presented for 305 
studies in support only).(21, 45, 51) Of these studies, data from two well-powered, national-306 
level studies from China supported cardiovascular disease and diabetes as risk factors for 307 







In this systematic review of risk factors for COVID-19 disease, disease severity and 313 
mortality, we document 33 comparative studies examining sociodemographic, behavioural 314 
and clinical exposures. Age and sex were very commonly examined; a wide array of 315 
comorbidities have also been considered. 316 
 317 
Within the synthesised evidence, risk factors for mortality were the clearest, plausibly partly 318 
because this outcome is easy to define. Increasing age (different studies presented different 319 
thresholds, but being over 50 years of age was common) was an uncontested risk factor. 320 
Five studies also presented evidence for the presence of any comorbidities being a risk 321 
factor,(21, 35, 46, 47, 51) with none demonstrating evidence against. Given the increasing 322 
prevalence of comorbidities with age, the lack of adjustment for confounding in these studies 323 
likely over-emphasises the effect size of each risk factor. We note that work subsequent to 324 
our literature search documents an independent effect of age on COVID-19 mortality from 325 
overall comorbidities, as measured by the Charlson Comorbidity Index Score, but not vice-326 
versa.(52) Another study published outside of the time range of our search found both age 327 
and an array of comorbidities, each analysed separately (chronic cardiac disease, chronic 328 
pulmonary disease, chronic kidney disease, chronic neurological disease, dementia, 329 
malignancy, moderate/severe liver disease; and obesity), to be independent risk factors (as 330 
well as sex).(53) 331 
 332 
Risk factors for severe disease were more complex to synthesise, likely due to the mixed 333 
array of outcome measures that can also be prone to observer bias. The impact of age was 334 
very commonly assessed, generally showing evidence in favour of this being a risk factor 335 
(with a similar age spectrum to the mortality data). Ethnicity was studied in two 336 
publications,(26, 30) with mixed results. We note that such findings are likely to be highly 337 
context-specific, given that ethnicity acts as a proxy for a series of sociodemographic factors 338 
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that are highly relevant to the spread of an infectious condition (as well as, perhaps, some 339 
biological traits). 340 
 341 
Studies of risk factors for COVID-19 disease have been complicated by testing strategies 342 
globally, which have largely been concentrated on severe disease. As our knowledge of the 343 
full symptom spectrum of the disease moves forward, it will be possible to have a broader 344 
case definition that does not solely focus on viral testing, and thus the ability for more 345 
generalised complementary studies. Additionally, serological surveys assessing the history 346 
of infection with SARS-CoV-2 in different population groups will allow the identification of risk 347 
factors for infection, whether symptomatic or not. Both ethnicity (Black and Asian individuals 348 
at higher risk; from a single study in England, Northern Ireland and Wales)(30) and higher 349 
BMI were found to be associated with disease severity within the included literature,(30, 37) 350 
again from descriptive studies only. While these studies were not eligible for our review, we 351 
note a series of reports from non-comparative studies documenting the potential influence of 352 
ethnicity on the likelihood of getting COVID-19 e.g. the work of Price-Haywood from the 353 
US.(52) Male sex was reasonably consistently shown to be a risk factor for presence of 354 
COVID-19 but not with severity of disease or mortality.(24, 30, 40) As with ethnicity, 355 
socioeconomic and behavioural factors make this association likely to vary between settings. 356 
 357 
In considering the role of comorbidities in COVID-19, it is important to consider the 358 
underlying pathology of the virus. Respiratory coronaviruses associated with the common 359 
cold in immunocompetent people generally affect only cells in the upper respiratory tract 360 
(URT), whereas the previously discovered highly pathogenic coronaviruses SARS-CoV and 361 
MERS-CoV affect cells in the URT and lower respiratory tract (LRT). SARS-CoV-2 has been 362 
shown to do the same,(54) and one of the host cell receptors it targets is Angiotensin-363 
Converting Enzyme 2 (ACE2), with a second major receptor being Transmembrane Serine 364 
Protease 2 (TMPRSS2).(55)  SARS-CoV-2 can infect all the major cell types in the 365 
respiratory tract – type I and type II pneumocytes, alveolar macrophages and endothelial 366 
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cells.(56, 57) This infection leads to cell death, with significant leaking of fluid into the 367 
alveolar spaces (pulmonary oedema), which compromises gas exchange,(58) eventually 368 
leading to ARDS. The inflammatory response adds aggregation of repair proteins such as 369 
fibrin, which can lead to creation of hyaline membranes which further reduces the surface 370 
available for gas exchange.(58) Subsequently, inflammatory cells are activated, recruited by 371 
release or exposure of cytokines such as the interleukins (IL) 1β and 6, monocyte 372 
chemoattractant protein-1,(56) and proteins of the extracellular matrix, as well as 373 
upregulation of the complement system. Inflammatory cells release cytokines which have 374 
systemic effects, eventually leading to disseminated intravascular coagulation (DIC), 375 
hypotensive shock and metabolic disturbances if not checked.(58) 376 
 377 
This pathogenesis therefore offers several points where co-morbidities may exacerbate the 378 
process. The target receptor TMPRSS2 is modulated in response to air pollution and in 379 
autoimmune conditions such as asthma,(55) which may affect the number of receptors 380 
available for SARS-CoV-2 to target, and ACE2 is involved in the renin-angiotensin system 381 
(RAS) which controls blood pressure. Viral interference causes dysfunction, which leads to a 382 
pro-inflammatory state and increased vascular permeability in response to changes in 383 
vascular contraction and sodium homeostasis – exacerbating the effect from the physical 384 
damage to the affected cells.(58) Conditions causing hypertension – both primary and 385 
secondary to renal disease, endocrine dysfunctions such as hypothyroidism, cardiovascular 386 
dysfunction such as arteriosclerosis, or neurological dysfunctions such as acute stress – 387 
also affect the RAS,(58) meaning that these conditions might be expected to exacerbate 388 
pathology caused by SARS-CoV-2. Any condition creating a pro-inflammatory state, such as 389 
type II diabetes or pre-existing infection, or involving autoimmunity, such as type I diabetes, 390 
might also be expected to contribute to increased pathology. There is also the direct effect of 391 
cell damage – if the target tissues are already damaged this reduces ‘spare’ capacity and 392 
therefore the leeway for adaptation to allow the host to continue to maintain homeostasis 393 
whilst still being able to eliminate the pathogen and repair the damage. The need for 394 
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inflammatory cells to clear the infection is also a potential area of interface with comorbidities 395 
e.g. conditions such as unsuppressed HIV infection, or congenital deficiencies, or cancer 396 
malignancies; or the administration of immunosuppressant drugs such as chemotherapy for 397 
cancer or steroids. 398 
 399 
The effect of ageing was particularly strong within our review, both in terms of the magnitude 400 
of effect estimates and the number of studies presenting evidence. As well as the above 401 
impact of comorbidities, we note that the host’s age may influence pathogenesis, both in 402 
terms of the likelihood of having various comorbidities, and also due to its effect on the 403 
immune system. Indeed, the immune system becomes less effective over time 404 
(immunosenescence), which affects the quality and number of immune system cells 405 
generated.(59) Given the scale of the impact of age documented within this review, it seems 406 
unlikely that its effect can be explained by a single or a small number of comorbidities which 407 
are yet to be detected. This opens up the need to explore biological markers, for example 408 
ACE2,(60) and markers of immunosenescence. 409 
 410 
The strengths of our review include its systematic approach and broad use of search terms 411 
to avoid missing studies. We additionally present a quality assessment to aid the 412 
interpretation of the strength of the evidence. In some instances, included publications may 413 
have focussed on one specific outcome, whereas our quality assessment took the 414 
perspective of the outcomes extracted for this review. We were unable to detect instances 415 
where two publications used the same patient populations for their analyses, potentially 416 
over-emphasising certain findings. Given the global nature of the pandemic, our review 417 
includes studies from around the world, albeit with a large preponderance from China, 418 
including studies conducted early after the emergence of SARS-CoV-2 when the at-risk 419 
population was predominantly those who had contact with Huanan seafood market and their 420 
contacts, and not necessarily representative of the general population. We note a particular 421 
lack of studies from the African continent and the Americas, which may have implications for 422 
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generalisability. Given the rapidly evolving literature on COVID-19, we also note our 423 
exclusion of studies published online after April 2020, for example the Dai report on cancer 424 
as a risk factor(61) and our exclusion of preprints (which was undertaken to ensure that all 425 
included studies had undergone an external quality assessment prior to inclusion).  426 
 427 
Across the included publications, variability in study design, exposure and outcome 428 
measurement, and analyses made exact syntheses of effect sizes across different risk 429 
factors very difficult. Measures of disease severity varied, e.g. admission to ICUs or clinical 430 
parameters such as percentage oxygen saturation of the blood. Even measures such as 431 
admission to ICU can be subjective and may be time-, clinician-, and health systems-432 
dependent. If severity is recorded at admission, risk factors may reflect issues associated 433 
with delayed access to healthcare, which may differ between settings and healthcare 434 
systems. It is also important to note that, in some studies of disease severity, mild disease 435 
included both people who were hospitalised with symptoms and asymptomatic individuals 436 
identified through contact tracing. Generally, analyses were descriptive or univariable and 437 
thus did not control for confounding. As documented above, this may be particularly 438 
problematic when it comes to separating the impact of age and the presence of 439 
comorbidities, as well as for identifying which comorbidities truly increase risk, given that 440 
many patients may have multi-morbidity.  441 
 442 
The implications of our findings are two-fold for COVID-19, firstly for current public health 443 
practice and secondly for the design of future studies. We flag a number of factors of interest 444 
that should be considered by governments and public health agencies when designing 445 
shielding strategies and the targeting of future vaccines, as well as in mathematical 446 
modelling projecting the likely impact of the pandemic over time. We note, however, the 447 
need for sensitive handling of population groups deemed to be at higher risk, and how such 448 
labelling does not devolve responsibility from public bodies to these individuals for their own 449 
welfare.(8) Some public health agencies are now including reporting of potential risk factors 450 
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in their routine outputs, including ICNARC (included in this review)(30) and the newer 451 
European Centre for Disease Prevention and Control reports, which were released after this 452 
review was conducted.(62) 453 
 454 
Our review demonstrates both the volume of literature that can be published within only a 455 
few months since the appearance of an emerging infectious disease, and the need for co-456 
ordinated approaches to such pathogens. Global efforts using national datasets are hugely 457 
valuable in systematically determining the aetiology of a disease, particularly to detect 458 
smaller effect sizes. Determination of the exact threshold of important risk depends on public 459 
perceptions of the disease,(63) as well as policy needs. Data collection should be 460 
standardised where possible, e.g. by using consistent definitions of outcomes and the 461 
treatment of exposures (for example for hypertension, given that blood pressure is 462 
continuous). (For COVID-19 we note both the valuable World Health Organization interim 463 
guidelines on its management in providing consistent approaches for testing and the 464 
definition of ARDS,(14) and that platforms such as the International Severe Acute 465 
Respiratory and Emerging Infections Consortium (ISARIC) have aimed to facilitate such 466 
standardisation.(64)) The choice of comparison groups should also merit careful 467 
consideration; comparison to other forms of the same condition (e.g. SARS and MERS for 468 
COVID-19), although interesting, provide little information about risk groups to be currently 469 
acted upon. Where key potential risk factors of interest, such as deprivation, are linked to 470 
both the disease of interest and the comparator condition, this limits the inferences possible. 471 
Saying this, studies of COVID-19 with the comparator group of other forms of viral 472 
pneumonia are a useful complement to studies using a general population comparator, as 473 
they show whether people with particular risk factors are at risk over and above what they 474 
might experience from ‘normal’ respiratory viruses, which might inform the level of additional 475 
precautions they could consider taking. 476 
 477 
Finally, appropriately adjusted multivariable analyses should be prioritised, in order to 478 
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separate the implications of different risk factors and to infer true causal relationships, for 479 
example exploring specific markers of comorbidity severity and control, such as the use of 480 
specific medications. We can then make the recommendations for shielding criteria more 481 
targeted, meaning that the public can be made more aware of the risk factors that are likely 482 
to have clinical significance and adapt their behaviour accordingly. Early clinical studies 483 
during pandemics are critically important and published rapidly under extremely difficult 484 
circumstances, but we would argue that high-quality epidemiological studies should also be 485 
seen as a priority, and that emergency response plans should include provision of 486 
appropriate epidemiological and statistical expertise.  487 
 488 
Conclusions 489 
The volume of literature generated in the short time since the appearance of SARS-CoV-2 490 
has been considerable. Many studies have sought to document the risk factors for COVID-491 
19 disease, disease severity and mortality. Age was the only risk factor based on robust 492 
studies and with a consistent body of evidence. Mechanistic studies are required to 493 
understand why age is such an important risk factor. At the start of pandemics, large, 494 
standardised, studies using multivariable analyses – e.g. using national surveillance data – 495 
are urgently needed in order to inform stratified approaches to rapidly protecting the 496 
population groups most at risk. 497 
 498 
  499 
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Figure legends 765 
Figure 1: PRISMA flow chart of selection 766 
 767 
Tables 768 
Table 1: UK risk groupings for COVID-19 disease as of 30th March 2020 769 
At risk of severe illness Shielding 
Aged 70 or older (regardless of medical 
conditions) 
 
Aged under 70 and*  
 Chronic (long-term) mild to moderate 
respiratory diseases, such as asthma, 
COPD, emphysema or bronchitis 
People with severe chest conditions such as cystic 
fibrosis or severe asthma (requiring hospital 
admissions or courses of steroid tablets) 
 Chronic heart disease, such as heart 
failure 
 
 Chronic kidney disease People with severe diseases of body systems, such 
as severe kidney disease (dialysis) 
 Chronic liver disease, such as hepatitis  
 Chronic neurological conditions, such as 
Parkinson’s disease, motor neurone 
disease, MS, a learning disability or 
cerebral palsy 
 
 Diabetes  
 A weakened immune system as the 
result of conditions such as HIV and 
AIDS, or medicines such as steroid 
tablets 
People who have received an organ transplant and 
remain on ongoing immunosuppression medication 
  People with cancer who are undergoing active 
chemotherapy or radiotherapy 
  People with cancers of the blood or bone marrow 
such as leukaemia who are at any stage of 
treatment 
 Being seriously overweight (a BMI of 40 
or above) 
 
Those who are pregnant  
Data taken from sources (9-11). *These groupings represent individuals advised to get a yearly 770 
influenza vaccine as an adult for medical reasons. BMI- body mass index, COPD- chronic obstructive 771 
pulmonary disease, MS- multiple sclerosis 772 
 773 
  774 
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Table 2: Included studies 















Definition of severity 















As per the international 
guidelines for community-
acquired pneumonia, with a 
scoring system based on 
demographics, comorbid illness, 
physical examination findings, 
and laboratory and radiographic 
findings 















Chen (21) Retrospective 







critically ill), single 
hospital 
274 Univariable N/A Death N/A 







Univariable N/A Disease N/A 





21 Univariable N/A Disease 
severity 
Severe meets any of the 
following criteria- respiratory 
distress, RR ≥ 30 breaths/min; 
SpO2 ≤ 93% at rest; and 
PaO2/FIO2 ≤300. Patients with 
greater than 50% lesion 
progression within 24 to 48 




















Definition of severity 
Cheng 
(24) 
















72314 Univariable N/A Death N/A 













cohort with a 
nested case-
control study 
Italy Hospitalised in ICU 
across 72 hospitals 






































Definition of severity 





273 Univariable N/A Disease 
severity 
Severe met at least one of the 
following conditions: a) 
shortness of breath, RR ≥ 30 
times/min, b) oxygen saturation 
(resting state) ≤93%, or c) 
PaO2/FiO2 ≤ 300mm Hg., in 
addition to positive SARS‐CoV‐2 
RNA nucleic acid test by 
Reverse transcription 
polymerase chain reaction, 
fever, or other respiratory 
symptoms (the typical CT image 
abnormities of viral pneumonia 
were optional). Critical patients 
also needed to meet at least one 
of the extra following conditions: 
a) respiratory failure that needs 
to receive mechanical 
ventilation; b) shock; and c) 
multiple organ failure that need 
























patients in ICU 






Univariable N/A Disease; 
Disease 
severity 
Receiving advanced, as 


























Definition of severity 



















Invasive ventilation, ICU 
admission, death 





119 Univariable N/A Disease 
severity 
Severe- dyspnoea accompanied 
by hypoxemia, sometimes acute 
respiratory distress syndrome, 
septic shock and multiple organ 
failure 







Age, sex Disease N/A 





36 Univariable N/A Disease 
severity 
Moderate disease (mild was 
baseline)- mild pneumonia; 
symptoms such as fever, cough, 
fatigue, headache, and myalgia; 
no complications and 
manifestations related to severe 
conditions 
Ruan (35) Retrospective 




patients across two 
hospitals with a 
definitive outcome 
150 Univariable N/A Death N/A 
Shi (36) Retrospective 
cohort 
China Hospitalised 












characterised by fever, cough, 
dyspnoea, bilateral pulmonary 






































Receiving invasive mechanical 
ventilation, determined when 
oxygen therapy (≥ 10 L/min) with 
target SpO2 (90-94%) was 
ineffective, and when RR was 
above 25/min, with signs of 
acute respiratory failure, despite 
maximal oxygen therapy 





the hospitals of 





diseases by Beijing 
Emergency 
Medical Service 
262 Univariable N/A Disease 
severity 
Severe- dyspnoea or respiratory 
failure in addition to fever, 
respiratory symptoms and 
radiographic evidence of 
pneumonia 





135 Univariable N/A Disease 
severity 
Severe group- respiratory 
distress, RR ≥ 30 breaths/minute 
in a resting state, a mean 
oxygen saturation of ≤93%, and 
an PaO2/FiO2 ≤ 300mmHg 
Wang 
(40) 
















































116 Univariable N/A Disease 
severity 
Severe- fever or suspected 
respiratory infection, plus one of 
the following: RR > 30 
breaths/min; severe respiratory 









69 Univariable N/A Disease 
severity 
SpO2 <90% 











ARDS, mechanical ventilation 
Wu (45) Prospective 
cohort 
China Country-wide data 44672 Univariable N/A Death N/A 









N/A Death N/A 













140 Univariable N/A Disease 
severity 
Severe COVID-19 was 
designated when the patients 
had one of the following criteria: 
(a) respiratory distress with 
respiratory frequency ≥30/min; 
(b) pulse oximeter oxygen 
saturation ≤93% at rest; and (c) 
oxygenation index (PaO2/FiO2) ≤ 

































95 Univariable N/A Disease 
severity 
Severe- RR ≥ 30 times / min; at 
rest, oxygen saturation ≤ 93%; 








120 Univariable N/A Disease 
severity 
Severe- when patients met one 
of the following criteria: (1) 
respiratory distress with a 
breathing rate ≥ 30/min; (2) pulse 
oximeter oxygen saturation ≤ 
93% at rest; (3) oxygenation 
index (PaO2/FiO2) ≤300 mmHg; 
(4) respiratory failure requiring 
mechanical ventilation; (5) 
shock; and (6) combined with 
other organ failure requiring ICU 
monitoring and treatment 
Zhou (51) Retrospective 




patients across two 















ARDS- acute respiratory distress syndrome, BMI- body mass index, CDC- Center for Disease Control and Prevention, CT- computed tomography, FiO2- 
inspired oxygen fraction, ICNARC- intensive care national audit and research centre, ICU- intensive care unit, MERS- Middle Eastern Respiratory Syndrome, 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cai (19) Y Y Y Y Y Y Y Y N N Y Y N/A N Y Y Y Y Y U Y 0 
Chen (20) Y Y Y Y N Y Y Y N U N Y N/A N Y Y Y Y N U Y 0 
Chen (21) Y Y Y Y N Y N N Y Y N N N/A N N/A Y Y Y N U N 0 
Chen (22) Y Y Y Y N Y N Y N N N N N/A N Y Y Y Y N U Y 0 
Chen (23) Y Y Y Y N Y N Y N U Y Y N/A N Y U Y Y N U Y 0 
Cheng (24) Y Y Y Y N Y N Y N N Y Y N/A N Y Y Y Y N U N 0 
Chinese 
CDC (25) 
Y Y Y Y Y Y N Y Y Y Y N N/A Y Y Y Y Y N U Y 5 
Fan (26) Y Y Y Y N Y N Y N N Y Y N/A N Y Y Y Y N U Y 0 
Grasselli 
(27) 
Y Y Y Y N Y Y Y N N Y Y N/A N Y Y Y Y N U Y 0 
Han (28) Y Y Y Y N Y N N N N N N N/A N N/A U Y Y N U Y 0 
Huang (29) Y Y Y Y N Y N Y Y Y Y Y N/A N Y Y Y Y N U Y 0 
ICNARC 
(30) 
Y Y N Y Y Y N N U U U U N/A N N/A U N N N U Y 4 
Liang (31) Y Y Y Y N Y Y Y N Y Y Y N/A Y Y Y Y Y Y Y Y 0 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Liu (33) Y Y Y Y N Y Y Y U U N N N/A N Y Y Y Y N U Y 3 
Qiu (34) Y Y Y Y N Y N Y N N Y Y N/A N Y U Y Y N U Y 0 
Ruan (35) Y Y Y Y N Y N Y N N Y Y N/A N Y Y Y Y N U Y 0 
Shi (36) Y Y Y Y N N Y Y N U U U N/A N Y U Y Y N U Y 0 
Simmonet 
(37) 
Y Y Y Y N Y Y Y N N Y Y N/A N Y Y Y Y N U Y 0 
Tian (38) Y Y Y Y N Y N Y N N Y Y N/A N Y U Y Y N U Y 0 
Wan (39) Y Y Y Y N Y N Y N N Y Y N/A N Y Y Y Y N U Y 0 
Wang (40) Y Y Y Y N Y N N N N N N N/A N N/A Y N N N U Y 0 
Wang (41) Y Y Y Y N Y N Y N U Y Y N/A N Y Y Y Y N U Y 0 
Wang (42) Y Y Y Y N Y N Y N U Y Y N/A N Y U Y Y N U Y 0 
Wang (43) Y Y Y Y N Y N Y N U N Y N/A N Y Y Y Y N U Y 0 
Wu (44) Y Y Y Y N Y Y Y N U N Y N/A Y Y U Y Y N Y Y 0 
Wu (45) Y Y Y Y N Y N N U U Y Y N/A N N/A Y Y Y N U Y 5 
Yang (46) Y Y Y Y N Y N N N U N Y N/A N N/A U Y Y N U Y 0 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Zhang (48) Y Y Y Y N Y N Y N U N N N/A N Y Y Y Y N U Y 0 
Zhang (49) Y Y Y Y N Y N Y N N N N N/A N Y Y Y Y N U N 0 
Zhang (50) Y Y Y Y N Y N Y U U N Y N/A N Y U Y Y N U Y 0 
Zhou (51) Y Y Y Y N Y Y Y N U N N N/A N Y Y Y Y N U Y 0 




Table 4: Potential risk factors for disease 
Potential risk 
factor 
Study supports risk Study does not support risk 
or is neutral 
Age Patients older than those with COVID-19 and 
younger than those with MERS 
(descriptive)(40) 
Younger ages (median 45 years) in patients 
with COVID-19 than other pneumonia (median 
61) (statistical test)(22) 
Increasing risk of positivity for SARS-CoV-2 
among COVID-19 suspects (on the basis of 
symptoms/contact tracing) with age (odds ratio 
1.02) but unclear categorisation of age 
(multivariable regression)(33) 
Median age 60 years in those 
with COVID-19 and 61 in those 
with other viral pneumonia 
(descriptive)(30) 
Mean age 50 years in COVID-
19 patients vs. 44 in individuals 
with other pneumonia (statistical 
test)(24) 
Sex Sex ratio skewed towards men for COVID-19, 
akin to MERS but not SARS (descriptive)(40) 
Sex ratio skewed towards men for COVID-19 
versus other viral pneumonia (descriptive)(30) 
Greater proportion male in COVID-19 versus 
other pneumonia, although small sample size 
and thus low statistical certainty (statistical 
test)(24) 
Increasing risk of positivity for SARS-CoV-2 
among COVID-19 suspects (on the basis of 
symptoms/contact tracing) among males 
versus female (odds ratio 1.16) (logistic 
regression)(33) 
Sex distribution similar amongst 
patients with COVID-19 and 
other pneumonia (statistical 
test)(22) 
Ethnicity Higher percentage of Black and Asian 
individuals amongst COVID-19 patients than 
patients with other viral pneumonias 
(descriptive)(30) 
 
Index of multiple 
deprivation 
 Distribution of deprivation 
similar across COVID-19 and 
other viral pneumonia 
(descriptive)(30) 
Body mass index Greater proportion of COVID-19 patients had 
higher body mass index than individuals with 
other pneumonia (descriptive)(37) 
Greater proportion of COVID-19 patients had 
higher body mass index than individuals with 
other viral pneumonia (descriptive)(30) 
 
Pregnancy  Percentage of women who were 
pregnant similar across COVID-
19 and other viral pneumonia 
(descriptive)(30) 




Table 5: Potential risk factors for disease severity 
Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Sex Odds ratio for severe disease 
3.68 for men compared to 
women (multivariable 
regression)(36) 
Odds ratio for invasive 
mechanical ventilation 2.83 for 
men compared to women 
(multivariable regression)(37) 
Females less likely to be 
admitted to ICU, require 
mechanical ventilation, or die; 
odds ratio 0.61 (multivariable 
logistic regression)(31) 
Sex distribution similar in severe 
and non-severe disease 
(descriptive)(30, 49)  
Sex distribution similar in severe 
and non-severe disease 
(statistical test)(23, 26, 28, 29, 
32, 34, 38, 39, 41-44, 48-50)  
Sex distribution similar in severe 
and non-severe disease 
(multivariable regression)(19, 
20) 
Age Average* 61 years severe 
disease, 45 otherwise (statistical 
test)(38) 
Average* 61 years severe 
disease, 52 years moderate 
disease (statistical test)(23) 
Average* 56 years severe 
disease, 44 years mild disease 
(statistical test)(39) 
Median 67 years acute 
respiratory distress syndrome, 
52 severe, 45 mild (statistical 
test)(42) 
Median 64 years severe 
patients, 52 years otherwise 
(statistical test)(48) 
Mean 61 years severe, 
otherwise 40 (statistical test)(50) 
Median 71 years SpO2<90%, 37 
years SpO2≥90% (statistical 
test)(43) 
Median 66 years patients in 
ICU, 51 otherwise (statistical 
test)(41) 
Median 54 years patients in 
ICU, 41 otherwise (statistical 
test)(26) 
65 years and over 3.26 times 
the hazard rate of ARDS than 
those under 65 (univariable 
regression)(44)  
Age associated with ICU 
admission, odds ratio 1.06 but 
unclear for what categorisation 
of age (multivariable 
regression)(20) 
Distribution of age did not differ 
by disease severity 
(descriptive)(30, 34, 49)  
Distribution of age did not differ 
by disease severity (statistical 
test)(28, 29, 32) 
Confidence interval for effect of 
age (categorisation unclear) 




Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Age continued Mean 56 years severe disease, 
45 years mild disease; odds 
ratio 1.06 but unclear 
categorisation of age 
(multivariable regression)(36) 
Mean 63 years severe disease, 
41 years mild disease; odds 
ratio 1.08 but unclear 
categorisation of age 
(multivariable regression)(19) 
Older individuals more likely to 
be admitted to ICU, require 
mechanical ventilation, or die; 
odds ratio 1.05, categories of 
age unclear (multivariable 
logistic regression)(31) 
 
Ethnicity 76.3% of individuals receiving 
basic respiratory support were 
White versus 65.6% receiving 
advanced respiratory support; 
Asian and Black ethnicities 
appear most at risk of severe 
disease (England, Northern 
Ireland and Wales; 
descriptive)(30) 
Distribution of disease severity 
similar across ethnic groups 
(Chinese, Malay, Indian, other – 
with small numbers in groups 
other than Chinese; study in 
Singapore; descriptive)(26) 
Deprivation  Distribution across deprivation 
categories similar 
(descriptive)(30) 
Pregnancy  Distribution in pregnant and 
non-pregnant individuals similar 
across disease severity 
(descriptive)(30) 
Smoking 100% of current smokers had 
severe disease, but only six 
individuals smoked(50) 
Distribution in current and non-
current smokers similar across 
disease severity (descriptive), 
only three individuals 
smoked(39) 
Distribution in current and non-
current smokers similar across 
disease severity (statistical test); 
small numbers who smoked 
(29) 
Distribution in historical/current 
and non-smokers similar across 
disease severity (statistical 
test)(36, 48) 
Body mass index ≥35kg/m2 risk factor versus 
<25kg/m2 for invasive 
mechanical ventilation; odds 
ratio 7.36. Results for other 
strata cross the null 
(multivariable regression)(37) 
Increasing body mass index 
increased risk; odds ratio 1.17 
(categorisation unclear)(19) 
Distribution of disease severity 




Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Any/other comorbidity Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(39, 41, 48, 50) 
Distribution with and without 
condition similar across disease 
severity (statistical test)(23, 29, 
36)  
Distribution with and without 
comorbidities not otherwise 
considered in the study similar 
across disease severity 
(statistical test)(50) 
Distribution with and without 




heart disease/coronary heart 
disease 
Presence of comorbidity more 
common among those with 
severe disease (descriptive)(39) 
Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(19, 36, 41, 43, 50) 
Distribution with and without 
condition similar across disease 
severity (descriptive)(30, 44) 
Distribution with and without 
condition similar across disease 
severity (statistical test)(29, 48) 
Hypertension Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(41, 43, 50) 
Hazard ratio of ARDS 1.82 in 
those with the condition versus 
those without (univariable 
regression)(44) 
Odds ratio of severe disease 
2.71 in those with the condition 
versus those without 
(multivariable regression)(36) 
Odds ratio of being admitted to 
ICU, require mechanical 
ventilation, or die 1.89 in those 
with the condition versus those 
without (multivariable 
regression)(31) 
Distribution with and without 
condition similar across disease 
severity (descriptive)(39) 
Distribution with and without 
condition similar across disease 
severity (statistical test); one 
study with small numbers with 
the condition(23, 29, 42, 48) 
Confidence interval in presence 
and absence of condition 
crosses the null (multivariable 
regression)(19) 
Confidence interval in presence 
and absence of condition 
crosses the null (multivariable 
regression, result 
borderline)(37) 
Diabetes Presence of comorbidity more 
common among those with 
severe disease (descriptive)(39) 
Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(19, 36, 41, 43, 50) 
Hazard ratio of ARDS 2.34 in 
those with the condition versus 
those without (univariable 
regression)(44) 
Odds ratio of being admitted to 
ICU, require mechanical 
ventilation, or die 2.21 in those 
with the condition versus those 
without (multivariable 
regression)(31) 
Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(23) 
Distribution with and without 
condition similar across disease 
severity (statistical test)(29, 48) 
Distribution with and without 
condition similar across disease 
severity (statistical test, 
borderline result)(42) 
Confidence interval in presence 
and absence of condition 
crosses the null (multivariable 
regression)(37) 
Respiratory/pulmonary disease  Distribution with and without 
condition similar across disease 
severity (descriptive)(30, 39) 
45 
 
Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Asthma  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition (43) 
Chronic obstructive pulmonary 
disease (COPD) 
Presence of comorbidity more 
common among those with 
severe disease (descriptive); 
small numbers with 
condition(39) 
Presence of comorbidity more 
common among those with 
severe disease (statistical test); 
both studies have small 
numbers with the condition(41, 
50) 
Odds ratio of being admitted to 
ICU, require mechanical 
ventilation, or die 3.40 in those 
with the condition versus those 
without (multivariable 
regression)(31) 
Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(29, 43, 
48) 
Pulmonary tuberculosis  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition (48) 
Malignancy Presence of comorbidity more 
common among those with 
severe disease (statistical test); 
small numbers with 
condition(39) 
Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(36, 42, 50)  
Presence of comorbidity more 
common among those with 
severe disease (multivariable 
analysis)(31) 
Distribution with and without 
condition similar across disease 
severity (descriptive)(30) 
Distribution with and without 
condition similar across disease 
severity (statistical test)(41) 
Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition (19, 29, 
43) 
Cerebrovascular disease Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(41) 
 
Arrhythmia  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with the condition(48) 
Cerebral infarction  Distribution with and without 
condition similar across disease 
severity (statistical test)(42) 
Stroke  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(48) 
Aorta sclerosis  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(48) 
46 
 
Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Chronic kidney disease/renal 
issues 
Presence of comorbidity more 
common among those with 
severe disease (statistical 
test)(42) 
Distribution with and without 
condition similar across disease 
severity (descriptive)(30) 
Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with the condition(41) 
Chronic renal disease/insufficiency  Distribution with and without 
condition similar across disease 
severity (statistical test); one 
study has small numbers of 
patients with the condition(36, 
48) 
Chronic liver disease  Distribution with and without 
condition similar across disease 
severity (descriptive), 
sometimes small numbers with 
condition(19, 30, 39) 
Distribution with and without 
condition similar across disease 
severity (statistical test)(36, 41) 
Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition (29, 50) 
 
 
Fatty liver and abnormal liver 
function 
 Distribution with and without 
condition similar across disease 
severity (statistical test)(48) 
Hyperlipidaemia  Distribution with and without 
condition similar across disease 
severity (statistical test)(48) 
Dyslipidemia  Confidence interval in presence 
and absence of condition 
crosses the null (multivariable 
regression)(37) 
Chronic gastritis/gastric ulcer  Distribution with and without 
condition similar across disease 
severity (statistical test)(48) 
Cholelithiasis  Distribution with and without 
condition similar across disease 
severity (statistical test)(48) 
Urolithiasis  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(48) 
Thyroid diseases  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with the condition(48) 
Electrolyte imbalance Presence of comorbidity more 
common among those with 
severe disease (statistical test); 
small numbers with 
condition(48) 
 
Agglomerative disease  Distribution with and without 
condition similar across disease 
severity (descriptive); small 
numbers with the condition(39) 
47 
 
Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Immunocompromised  Distribution with and without 
condition similar across disease 
severity (descriptive)(30) 
Chronic hepatitis  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(43) 
HIV  Distribution with and without 
condition similar across disease 
severity (statistical test); small 
numbers with condition(41) 
Living without assistance  Distribution with and without 
condition similar across disease 
severity (descriptive)(30) 
One study included death in a combined measure of disease severity.(31) *Unclear as to whether 
mean, median or mode. ARDS- acute respiratory distress syndrome, ICU- intensive care unit, 





Table 6: Potential risk factors for mortality 
Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Sex Men more at risk 
(descriptive)(21) 
Sex distribution similar amongst 
patients who died and survived 
(descriptive)(25, 35, 46, 47) 
Confidence interval for males 
versus females crosses the null 
(univariable regression)(44) 
Age Over 60 years particular at risk 
(descriptive)(21) 
8% case fatality ratio in 70-79 
year olds and 14.8% in those 
over 80. Overall figure 2.3% 
(descriptive)(45) 
Median age in those who died 
52 years, 65 years among 
survivors (descriptive)(46) 
Over 50 years of age 
particularly at risk- 1.3% died 
50-59 years, 3.6% 60-69 years, 
8.0% 70-79 years, 14.8% 80 
years plus; less than 1% all 
other age groups 
(descriptive)(25) 
Risk begins to increase at 
approximately 50 years 
(statistical test, but graphical 
presentation)(35) 
Median age in those who died 
68 years, among those who 
survived 55 (statistical test)(47) 
Over 61 years, increasing per 
10 year age group (statistical 
test)(27) 
65 years and older 6.17 the 
hazard rate of those under 65 
(univariable regression)(44) 
 
Smoking  Proportion of smokers similar 
among those who died versus 
those who did not (descriptive) ; 
one study had small numbers of 
smokers (21, 46) 
Distribution of current smokers 
similar among survivors and 
non-survivors (univariable 
regression analysis, not 
included in multivariable 
model)(51) 
Pregnancy  Proportion of women who were 
pregnant similar amongst 
patients who died versus 
survived (descriptive)(21) 
Any comorbidity Presence of any comorbidity 
more common among those 





Potential risk factor Study supports risk Study does not support risk 
or is neutral 
Hypertension Presence of condition more 
common among those dying 
(descriptive)(3, 21, 25, 27) 
Presence of condition more 
common among those dying 
(statistical test)(47, 51) 
Confidence interval for 
individuals with and without the 




Presence of condition more 
common among those dying 
(descriptive)(21, 25, 35, 45) 
Presence of condition more 
common among those dying 
(statistical test)(47, 51) 
Distribution dying in presence 
and absence of comorbidity 
similar (descriptive), sometimes 
small numbers with the 
condition(44, 46) 
Diabetes Presence of condition more 
common among those dying 
(descriptive)(21, 25, 45, 46) 
Presence of condition more 
common among those dying 
(statistical test)(47, 51) 
Confidence interval for 
individuals with and without the 
condition crosses the null 
(univariable regression)(44) 
Chronic respiratory/lung disease 
(chronic obstructive lung disease) 
Presence of condition more 
common among those dying 
(descriptive)(21, 45) 
Presence of condition more 
common among those dying 
(statistical test)(51) 
Distribution dying in presence 
and absence of comorbidity 
similar (descriptive)(46) 
Respiratory infectious disease Presence of condition more 
common among those dying 
(descriptive)(25) 
 
Malignancy Presence of condition more 
common among those dying 
(descriptive)(3, 25) 
Distribution dying in presence 
and absence of comorbidity 
similar (descriptive), sometimes 
small numbers with the 
condition(46, 47, 51) 
Cerebral infarction/ 
cerebrovascular disease 
Presence of condition more 
common among those dying 
(descriptive)(46) 
Distribution dying in presence 
and absence of comorbidity 
similar (statistical test); small 
numbers with the condition(47) 
Chronic gastritis  Distribution dying in presence 
and absence of comorbidity 
similar (statistical test); small 
numbers with the condition(47) 
Chronic kidney disease Presence of condition more 
common among those dying 
(statistical test); small numbers 
with the condition (51) 
 
Dementia  Distribution dying in presence 
and absence of comorbidity 
similar (descriptive); small 
numbers with the condition(46) 
Malnutrition  Distribution dying in presence 
and absence of comorbidity 
similar (descriptive); small 
numbers with the condition(46) 
Hepatitis B virus infection  Distribution dying in presence 
and absence of comorbidity 
similar (descriptive)(21) 
 
 
